Get the Stockscreener App
990.33
0.72%
7.07
After Hours:
985.00
-5.33
-0.54%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $990.33, with a volume of 2.62M.
It is up +0.72% in the last 24 hours and down -6.41% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$983.26
Open:
$975
24h Volume:
2.62M
Relative Volume:
0.82
Market Cap:
$884.36B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
43.84
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-5.86%
1M Performance:
-6.41%
6M Performance:
+36.18%
1Y Performance:
+8.50%
1-Day Range:
$966.09
$991.22
1-Week Range:
$965.60
$1,056.20
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
990.33 | 878.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
240.40 | 577.48B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
230.11 | 410.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
160.12 | 307.23B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.22 | 306.31B | 58.80B | 10.24B | 8.98B | 3.2788 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market? - The Motley Fool
Mounjaro weight loss trend: What Lilly’s hot drug really means for you - AD HOC NEWS
WHO Foundation announces collaboration with Lilly to strengthen health systems for obesity care | Corporate - EQS News
Chief technology officer spent whole career at Lilly - Indianapolis Business Journal
Morgan Stanley reiterates Overweight on Eli Lilly stock, $1,313 target By Investing.com - Investing.com India
Eli Lilly (LLY) Partners with GoodRx for Expanded Access to Zepb - GuruFocus
Eli Lilly: The One-Way Ride Can't Last Forever (Rating Downgrade) (NYSE:LLY) - Seeking Alpha
Talking Business with Don Cunningham: With Eli Lilly in the Valley, a life sciences flower blooms - The Morning Call
UBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,250 - 富途牛牛
Integrity Advisory Solutions LLC Makes New $1.07 Million Investment in Eli Lilly and Company $LLY - MarketBeat
Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president - Endpoints News
Pitcairn Co. Sells 1,346 Shares of Eli Lilly and Company $LLY - MarketBeat
Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli LillyRoche Holding (OTC:RHHBY) - Benzinga
‘Project Kennedy’: An inside look at the effort to bring Eli Lilly to Pa.’s Lehigh Valley | Opinion - lehighvalleylive
Upper Macungie approves tax breaks for Eli Lilly’s proposed manufacturing campus - WFMZ.com
Lilly targets employers in new bid to broaden access to obesity drugs - HR Dive
Eli Lilly and Company (NYSE:LLY) Trading Down 2.1%Here's Why - MarketBeat
Eli Lilly Just Launched a New Program to Make GLP‑1 Weight‑Loss Drugs Cheaper for Millions of Workers - inc.com
Teladoc Health joins Eli Lilly Employer Connect platform to expand workplace health options - Traders Union
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? - AOL.com
Morgan Stanley reiterates Eli Lilly stock rating on new obesity platform - Investing.com
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? - Yahoo Finance UK
Eli Lilly (LLY) Launches Employer Connect for Obesity Drug Acces - GuruFocus
Eli Lilly and Company $LLY Shares Sold by Orion Porfolio Solutions LLC - MarketBeat
Eli Lilly Targets Employer Coverage Gap With New Obesity Drug Access Platform - Benzinga
This Under-the-Radar Stock Could Be the Next Big SplitAnd Early Investors Could Win Big - AOL.com
Lilly launches employer platform for obesity drug access - Investing.com
Eli Lilly and Co's first large-scale AI factory worldwide has been put into operation, equipped with over 1,000 GPUs. - 富途牛牛
Lilly launches employer-connect platform to broaden weight-loss drug access - Reuters
Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance - statnews.com
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S. - CNBC
Quantbot Technologies LP Cuts Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Acquired by Davidson Capital Management Inc. - MarketBeat
Crossmark Global Holdings Inc. Sells 1,008 Shares of Eli Lilly and Company $LLY - MarketBeat
Corient IA LLC Acquires 1,000 Shares of Eli Lilly and Company $LLY - MarketBeat
Cambria Investment Management L.P. Purchases 1,026 Shares of Eli Lilly and Company $LLY - MarketBeat
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients - Eli Lilly and Company
Eli Lilly confirms oral GLP-1 weight-loss drug being evaluated by TGA - AFR
Eli Lilly’s Nvidia AI Deal And Pipeline Progress Versus Rich Valuation - simplywall.st
Eli Lilly and Company completed the acquisition of Ventyx Biosciences, Inc. from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others. - marketscreener.com
Eli Lilly and booming weight-loss pharma industry now 20% of Irish goods exports - Irish Examiner
Ventyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq - Investing.com India
Eli Lilly Unusual Options Activity For March 04 - Benzinga
Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval - Reuters
Eli Lilly & Co (NYSE:LLY): A High-Growth Dividend Stock for Discerning Investors - ChartMill
Richard C. Young & CO. LTD. Makes New $13.88 Million Investment in Eli Lilly and Company $LLY - MarketBeat
Picton Mahoney Asset Management Lowers Holdings in Eli Lilly and Company $LLY - MarketBeat
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
2 Top Growth Stocks to Buy in the First Half of 2026 - AOL.com
Does Lilly’s Broad Pipeline Wins in Obesity and Immunology Reshape the Bull Case for LLY? - simplywall.st
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.32%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):